HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

AIDS

Volumn 13, Issue 15, 1999, Pages 2003-2012

  Pinto, Ligia A ^a   Berzofsky, Jay A ^a   Fowke, Keith R ^a   Little, Richard F ^a   Merced Galindez, Fiorentino ^a   Humphrey, Rachel ^a   Ahlers, Jeffrey ^a   Dunlop, Nancy ^a   Cohen, Roger B ^a   Steinberg, Seth M ^a   Nara, Peter ^a   Shearer, Gene M ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocytes; HIV 1 envelope; HIV 1 patients; Peptide vaccine; T helper responses

Indexed keywords

DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONTANIDE ISA 51; PCLUS 3 18 MN; PCLUS 6.1 18 MN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE COUNT; MONONUCLEAR CELL; MYALGIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS IMMUNITY;

ADULT; AIDS VACCINES; HISTOCOMPATIBILITY TESTING; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNIZATION; NEUTRALIZATION TESTS; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 0032708913     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00002     Document Type: Article

References (54)

1. Sattentau QJ. Neutralization of HIV-1 by antibody. Curr Opin Immunol 1996, 8: 540-545.
2. Berzofsky JA, Berkower IJ. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995. AIDS 1995, 9(Suppl A):S143-S147.
3. Pinto LA, Sullivan J, Berzofsky JA, et al. Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995, 96:867-876.
4. Fowke K, Nagelkerke NJD, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996, 348:1347-1351.
5. Rowland Jones, SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995, 7:448-455.
6. Cheynier, R, Langlade-Demoyen P, Marescot MR, et al. Cytotoxic T lymphocyte response in peripheral blood of children born to HIV1 infected mothers. Eur J Immunol 1992, 22:2211-2217.
7. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
8. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term non progressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
9. Koup RA, Safrit JT, Cao Y, Ho D. Temporal association of cellular immune responses with the initial control of viremia in primary immunodeficiency virus type 1 syndrome. J Virol 1994, 179:4650-4655.
10. Safrit JT, Andrews CA, Zhu D, Ho D, Koup RA. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. J Exp Med 1994, 179:463-472.
11. Rosenberg ES, Billingsley JM, Callendo AM, et al. Vigorous HIV-1-specific CD4 T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
12. Bangham CR, Phillips RE. What is required of an HIV vaccine. Lancet 1997, 350:1617-1621.
13. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
14. Hale PM, Cease KB, Houghten RA, et al. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. Int Immunol 1989, 1:409-415.
15. Berzofsky JA, Pendleton CD, Clerici M, et al. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest 1991, 88:876-884.
16. Takahashi H, Cohen J, Hosmalin A, et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988, 85:3105-3109.
17. Clerici M, Lucey DR, Zajac RA, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991, 146: 2214-2219.
18. Achour A, Picard O, Mbika J-P, et al. Envelope protein and p18 (IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. Vaccine 1993, 11:699-701.
19. Ahlers JD, Pendleton CD, Dunlop N, et al. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J Immunol 1993, 150:5647-5655.
20. + CTL in vivo with peptide vaccine constructs. J Immunol 1994, 152:549-556.
21. Ahlers JD, Dunlop N, Pendleton CD, et al. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996, 12:259-272.
22. Curgo C, Guo HC, Franchini G, et al. Envelope sequences of two new United States HIV-1 isolates. Virology 1988, 164:531-536.
23. LaRosa GJ, Davide JP, Weinhold K, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249:932-935.
24. Myers G, Joseph SF, Berzofsky JA, et al. Human Retroviruses and AIDS. Los Alamos, New Mexico: Los Alamos National Laboratory; 1989.
25. Wittes RE. Common toxicity criteria for cancer clinical trials. In Manual of Oncologic Therapeutics. Edited by Wittes RE. Philadelphia, PA: Lippincott; 1991:445.
26. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
27. Stewart JM, Young JD. Solid Phase Peptide Synthesis. Rockford, IL: Pierce Chemical Company; 1994.
28. Clerici M, Stocks NI, Zajac RA, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989, 339:383-385.
29. Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R. Transfer and expression of three cloned human non-HLA-A, -B, -C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci USA 1988, 85:227-231.
30. Nara PL, Hatch WC, Dunlop NM, et al. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 1987, 3:283-302.
31. Boom R, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990, 28:495-503.
32. Mulder J, McKinney N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994, 32:292-300.
33. Vardtal F, Gaudernack C, Funderud S, et al. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation - a fast and reliable technique. Tissue Antigens 1989, 28:301-312.
34. Scharf SJ, Griiffith RL, Elrich HA. Rapid typing of DNA sequence polymorphism at the HLA-DRb1 locus suing the polymerase chain reaction and nonradioactive oligonucleotide probes. Hum Immunol 1991, 30:190-201.
35. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800.
36. Smith MC, Pendleton CD, Maher VE, et al. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing. Int Immunol 1997, 9:1085-1093.
37. Cavacini L A, Ernes CL, Power J, et al. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993, 6:353-358.
38. Larsen HL, Feng MF, Horohov DW, Moore RN, Rouse BT. Role of T lymphocyte subsets in recovery from herpes simplex. J Virol 1984, 50:56-59.
39. Clerici M, Giorgi JV, Chou C-C, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019.
40. Planz O, Ehl S, Furrer E, et al. A critical role for neutralizing antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997, 94:6874-6879.
41. Bennett SR, Carbonne FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998, 393:478-480.
42. + T-helper and a T-killer cell. Nature 1998, 393:474-478.
43. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
44. + T cell-mediated antiviral activity. J Immunol 1999; 162:2867-2874.
45. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998 ,4:321-327.
46. Eron JJ Jr, Ashby MA, Giordano MF, et al. Randomized trial of MNrgp120 HIV vaccine in symptomless HIV infection. Lancet 1996, 348:1547-1551.
47. Fowke KR, D'Amico R, Chernoff DN et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1 infected patients. AIDS 1997, 11:1013-1021.
48. Gulukota K, DeLisi C. HLA allele selection for designing peptide vaccines. Genet Anal 1996, 13:81-86.
49. Yarchoan, R., Mitsuya H, Broder S. Challenges in the therapy of HIV infection. Immunol Today 1993, 14:303-309.
50. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
51. Butini L, Regnery CM, Menzo S, Montroni M. HIV-specific CTL dynamics in response to HAART. Sixth Conference on Retroviruses and Oportunistic infections. Chicago, February 1999 [abstract 341].
52. + T cell response is not restored after 28 months of HAART with viral load < 50 copies. Sixth Conference on Retroviruses and Oportunistic infections. Chicago, February 1999 [abstract 343].
53. Ortiz GM, Jin X, Demoitie MA, et al. Containment of break-through HIV plasma viremia in the absence of antiretroviral drug therapy is associated with a broad and vigorous HIV specific CTL response. Sixth Conference on Retroviruses and Oportunistic infections. Chicago, February 1999 [abstract 256].
54. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999, 5:518-525.